Interleukin-23 Antagonist [EPC]

60309 reported adverse events

Drugs of this class: GUSELKUMAB TILDRAKIZUMAB-ASMN USTEKINUMAB

These side effects are most commonly reported by patients taking drugs of the Interleukin-23 Antagonist [EPC] class:

# Side effect Count
0 DRUG INEFFECTIVE 7148
1 OFF LABEL USE 5293
2 PSORIASIS 5007
3 PRODUCT USE ISSUE 2604
4 CROHN^S DISEASE 2446
5 PRODUCT DOSE OMISSION 2284
6 PNEUMONIA 2200
7 DRUG DOSE OMISSION 2040
8 LOWER RESPIRATORY TRACT INFECTION 2016
9 HEADACHE 1966
See all common reactions for Interleukin-23 Antagonist [EPC]

Drugs of the Interleukin-23 Antagonist [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 RED BLOOD CELL SEDIMENTATION RATE 33 0.3056
1 SWOLLEN JOINT COUNT INCREASED 29 0.2566
2 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE 212 0.2431
3 CONTRAINDICATION TO VACCINATION 37 0.2357
4 ENTHESOPATHY 145 0.1975
5 ERYTHRODERMIC PSORIASIS 82 0.1507
6 ILEECTOMY 27 0.1475
7 SYRINGE ISSUE 876 0.1455
8 CUTANEOUS T-CELL LYMPHOMA 39 0.1403
9 RHEUMATOID FACTOR POSITIVE 202 0.1348
See all enriched reactions for Interleukin-23 Antagonist [EPC]